ClinicalTrials.gg
CompletedNCT03330314Updated Aug 12, 2020

Molar Potency Study of HM12460A in Healthy Subjects

A Phase 1 interventional study of HM12460A in Healthy Volunteers, sponsored by Hanmi Pharmaceutical Company Limited. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-08-12.

Sponsored by Hanmi Pharmaceutical Company Limited · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Feb 2018, 8 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This is a phase 1 study to assess and compare molar potency of HM12460A and glargine in healthy subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Hanmi Pharmaceutical Company Limited is the lead sponsor of 191 studies on the registry; 12 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Females must be non-pregnant and non-lactating
  • Males must be surgically sterile or using an acceptable method

Exclusion criteria

Exclusion Criteria:

  • History of any major surgery within 6 months prior to screening
  • Use of any new prescription or non-prescription drug in the last 30 days
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
38 participants (actual)

Study arms

  • Experimental
    Part 1

    Intravenous (IV) infusion

    Biological: HM12460A

  • Experimental
    Part 2: Cohort A

    Intravenous (IV) infusion (Dose A)

    Biological: HM12460A

  • Experimental
    Part 2: Cohort B

    Intravenous (IV) infusion (Dose B)

    Biological: HM12460A

  • Experimental
    Part 2: Cohort C

    Intravenous (IV) infusion (Dose C)

    Biological: HM12460A

Interventions

  • BiologicalHM12460A

    HM12460A is a long-acting insulin

06

What researchers measure

Primary outcomes

  1. Blood glucose assessment of HM12460A and insulin glargine over the entire dosing period

    - Comparison of HM12460A to insulin glargine based on blood glucose profile generated by intravenous infusion

    Time frame: 1 month

Secondary outcomes

  1. Cmax of HM12460A

    - Maximum concentration of HM12460A over the entire dosing period

    Time frame: 1 month

  2. AUC of HM12460A

    - Area Under the Curve of HM12460A over the entire dosing period

    Time frame: 1 month

07

Study locations

1 site
  • Hanmi Investigative Site
    Chula Vista, California 91911, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Feb 2018, 3 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2017
First posted
Nov 6, 2017
StartActual
Oct 24, 2017
Primary completionActual
Feb 8, 2018
CompletionActual
Feb 8, 2018
Last update
Aug 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03330314
Responsible party
Sponsor
First posted
Nov 6, 2017
Start date
Oct 24, 2017
Primary completion
Feb 8, 2018
Completion
Feb 8, 2018
Last update
Aug 12, 2020

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HM12460A

Start the discussion